It is widely recognized that macrophages (M/M) represent a crucial target of HIV-1 in the body and play a pivotal role in the pathogenic progression of HIV-1 infection. This strongly supports the clinical relevance of therapeutic strategies able to interfere with HIV-1 replication in M/M. In vitro studies showed that nucleoside analogue inhibitors of HIV-1 reverse transcriptase have potent antiviral activity in M/M, although the limited penetration of these compounds in sequestered body compartments and low phosphorylation ability of M/M, suggest that a phosphonate group linked to NRTIs may confer greater anti-HIV-1 activity in M/M. Differently, the antiviral activity of non-nucleoside reverse transcriptase inhibitors in M/M is similar to that found in CD4+ lymphocytes. Interestingly, protease inhibitors, acting at a post-integrational stage of HIV-1 life-cycle are the only drugs active in chronically infected M/M. A careful analysis of the distribution of antiviral drugs, and the assessment of their activity in M/M, represent key factors in the development of therapeutic strategies aimed to the treatment of HIV-1-infected patients. Moreover, testing new and promising antiviral compounds in such cells may provide crucial hints about their efficacy in patients infected by HIV. © 2006 Elsevier B.V. All rights reserved.

Perno, C.f., Svicher, V., Schols, D., Pollicita, M., Balzarini, J., Aquaro, S. (2006). Therapeutic strategies towards HIV-1 infection in macrophages. ANTIVIRAL RESEARCH, 71(2-3 SPEC. ISS.), 293-300 [10.1016/j.antiviral.2006.05.015].

Therapeutic strategies towards HIV-1 infection in macrophages

PERNO, CARLO FEDERICO;SVICHER, VALENTINA;POLLICITA, MICHELA;AQUARO, STEFANO
2006-01-01

Abstract

It is widely recognized that macrophages (M/M) represent a crucial target of HIV-1 in the body and play a pivotal role in the pathogenic progression of HIV-1 infection. This strongly supports the clinical relevance of therapeutic strategies able to interfere with HIV-1 replication in M/M. In vitro studies showed that nucleoside analogue inhibitors of HIV-1 reverse transcriptase have potent antiviral activity in M/M, although the limited penetration of these compounds in sequestered body compartments and low phosphorylation ability of M/M, suggest that a phosphonate group linked to NRTIs may confer greater anti-HIV-1 activity in M/M. Differently, the antiviral activity of non-nucleoside reverse transcriptase inhibitors in M/M is similar to that found in CD4+ lymphocytes. Interestingly, protease inhibitors, acting at a post-integrational stage of HIV-1 life-cycle are the only drugs active in chronically infected M/M. A careful analysis of the distribution of antiviral drugs, and the assessment of their activity in M/M, represent key factors in the development of therapeutic strategies aimed to the treatment of HIV-1-infected patients. Moreover, testing new and promising antiviral compounds in such cells may provide crucial hints about their efficacy in patients infected by HIV. © 2006 Elsevier B.V. All rights reserved.
2006
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
English
Con Impact Factor ISI
Antiretroviral drugs; CD4+ lymphocytes; HIV-1; Macrophages
Perno, C.f., Svicher, V., Schols, D., Pollicita, M., Balzarini, J., Aquaro, S. (2006). Therapeutic strategies towards HIV-1 infection in macrophages. ANTIVIRAL RESEARCH, 71(2-3 SPEC. ISS.), 293-300 [10.1016/j.antiviral.2006.05.015].
Perno, Cf; Svicher, V; Schols, D; Pollicita, M; Balzarini, J; Aquaro, S
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons Creative Commons

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/43381
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 35
social impact